FDA backs Novartis’ Gilenya in paediatric MS
First disease modifying therapy approved in paediatric MS
X
FDA backs Novartis’ Gilenya in paediatric MS
https://pharmaphorum.com/news/fda-backs-novartis-gilenya-in-paediatric-ms/
paediatric
Paediatric Clinical Trials 2018
Paediatric Clinical Trial
Novartis plans filing for Gilenya in paediatric MS
PARADIGM study meets primary endpoint.
GW close to filing cannabis-based epilepsy drug
Epidiolex could become a blockbuster if approved in all uses.
EUSA Pharma approval fills gap in neuroblastoma market
Company can move in after United Therapeutics withdrew its product Unituxin
Shire’s rare disease duo gain “Breakthrough” status
FDA to provide guidance during development.
